COVID-19 Self-testing IMPROVE

Project IMPROVE: Implementing Community-Engaged Intervention Research to Increase Rapid SARS-CoV-2 Self-Testing Among Diverse Underserved and Vulnerable Asian Americans

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06576167

Enrollment

1277

Registered

2024-08-28

Start date

2023-06-15

Completion date

2025-03-15

Last updated

2026-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The study aims to engage community partners to implement IMPROVE intervention and promote (COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia Area and New York City

Interventions

BEHAVIORALIMPROVE

IMPROVE is a CBHN-led intervention. The study team delivered comprehensive training to CHNs to let them be well-prepared for intervention delivery. CHNs lead an in-person start-up group education session that consists of 4 modules: 1) a 6-minutes video of a health care provider delivering information on COVID-19 to help participants better understand the disease; 2) using educational slides, CHNs discuss the importance of COVID-19 testing and mitigation adherence; 3) CHNs conduct live demonstration of how to use rapid COVID-19 self-test kit correctly and distribute two COVID-19 self-testing kits to each participant. 4) CHNs guide interactive discussions with participants to enable them to reflect and reinforce what they learned. In addition, CHNs will help participants identify their navigation needs in reducing hesitancy of self-testing and mitigation practices. CHNs will also schedule check-in calls with participants.

Study design

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

SCREENING

Masking

NONE

Intervention model description

stepped wedge clustered-randomized trial

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* (1) self-identified as Asian from one of the subgroups: Chinese, Korean, Vietnamese, Filipino, or other South Asian Americans, * (2) aged 18 and above, * (3) living in the Greater Philadelphia or NYC areas,

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Lifetime Rate of COVID-19 Home Self-Testing Kit Use	baseline, 1-month follow up, and 3-month follow up	Lifetime use defined as self-report of ever using a COVID-19 rapid antigen home self-test kit at least once. Baseline was collected before IMPROVE implementation for all participants. The 1-month and 3-month follow-up assessments were collected after participants received the IMPROVE intervention, according to their wedge rollout schedule. Cleaned dataset with corrected data collection dates was used to update the results.

Countries

United States

Baseline characteristics

Characteristic	—
Age, Continuous	61.13 years
Race (NIH/OMB) American Indian or Alaska Native	0 Participants
Race (NIH/OMB) Asian	361 Participants
Race (NIH/OMB) Black or African American	0 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	0 Participants
Sex: Female, Male Female	290 Participants
Sex: Female, Male Male	133 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	0 / 1,277	0 / 1,277	0 / 1,060
other Total, other adverse events	0 / 1,277	0 / 1,277	0 / 1,060
serious Total, serious adverse events	0 / 1,277	0 / 1,277	0 / 1,060

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 21, 2026